JS 026
Alternative Names: JS-026Latest Information Update: 11 Aug 2023
At a glance
- Originator Shanghai Junshi Biosciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 08 Dec 2022 Shanghai Junshi Bioscience completes a phase I trials in COVID-2019 infections (Monotherapy, Combination therapy, In volunteers) in China (IV) (NCT05167279)
- 17 Dec 2021 Phase-I clinical trials in COVID-2019 infections (In volunteers, In adults, Combination therapy) in China (IV) (NCT05167279)
- 17 Dec 2021 Phase-I clinical trials in COVID-2019 infections (Monotherapy, In adults, In volunteers) in China (IV) (NCT05167279)